Literature DB >> 12163218

Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath.

Andrew J S Coats1.   

Abstract

Cachexia is a complication of many disorders. It is associated with an extremely poor prognosis and many symptoms. The wasting process affects particularly skeletal muscle causing extreme fatigue and weakness. In many underlying conditions associated with cachexia, the patient also suffers an often unexplained severe dyspnoea along with weakness, asthenia and exhaustion. There appears to be marked similarities in the cause of dyspnoea and fatigue between different cachectic conditions. Using the example of cardiac cachexia, this article reviews the evidence linking skeletal muscle reflex inputs to ventilatory control and exaggerated chemoreflex responses as candidates for the heightened perception of dyspnoea which cannot be explained by heart or lung dysfunction in many patients. Evidence is reviewed that similar processes may occur in other cachexias, especially those complicating cancer, AIDS, chronic liver disease, and chronic lung disease. Potential novel therapeutic strategies to combat these cachexia symptoms are reviewed.

Entities:  

Mesh:

Year:  2002        PMID: 12163218     DOI: 10.1016/s0167-5273(02)00242-5

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

Review 1.  Aspects of physical medicine and rehabilitation in the treatment of deconditioned patients in the acute care setting: the role of skeletal muscle.

Authors:  Michael Quittan
Journal:  Wien Med Wochenschr       Date:  2016-01-12

Review 2.  Targeting the myostatin signaling pathway to treat muscle wasting diseases.

Authors:  H Q Han; William E Mitch
Journal:  Curr Opin Support Palliat Care       Date:  2011-12       Impact factor: 2.302

Review 3.  Symptom perception in CHF: (why mind matters).

Authors:  Christine E Skotzko
Journal:  Heart Fail Rev       Date:  2007-12-11       Impact factor: 4.214

4.  Induction of muscle weakness by local inflammation: an experimental animal model.

Authors:  S Bicer; P J Reiser; S Ching; N Quan
Journal:  Inflamm Res       Date:  2009-04       Impact factor: 4.575

5.  Cancer cachexia alters intracellular surfactant metabolism but not total alveolar surface area.

Authors:  Tilman Graulich; Suman Kumar Das; Gabriela Krasteva; Clemens Ruppert; Lars Wessels; Gerald Hoefler; Christian Mühlfeld
Journal:  Histochem Cell Biol       Date:  2012-07-19       Impact factor: 4.304

Review 6.  Muscle wasting in disease: molecular mechanisms and promising therapies.

Authors:  Shenhav Cohen; James A Nathan; Alfred L Goldberg
Journal:  Nat Rev Drug Discov       Date:  2015-01       Impact factor: 84.694

7.  Testosterone deficiency increases hospital readmission and mortality rates in male patients with heart failure.

Authors:  Marcelo Rodrigues dos Santos; Ana Luiza Carrari Sayegh; Raphaela Vilar Ramalho Groehs; Guilherme Fonseca; Ivani Credidio Trombetta; Antônio Carlos Pereira Barretto; Marco Antônio Arap; Carlos Eduardo Negrão; Holly R Middlekauff; Maria-Janieire de Nazaré Nunes Alves
Journal:  Arq Bras Cardiol       Date:  2015-07-21       Impact factor: 2.000

8.  Moderate-Intensity Exercise Improves Body Composition and Improves Physiological Markers of Stress in HIV-Infected Men.

Authors:  Wesley David Dudgeon; Jason Reed Jaggers; Kenneth Doyle Phillips; John Larry Durstine; Stephanie E Burgess; George William Lyerly; John Mark Davis; Gregory Alan Hand
Journal:  ISRN AIDS       Date:  2012-12-11

9.  Petri net-based prediction of therapeutic targets that recover abnormally phosphorylated proteins in muscle atrophy.

Authors:  Jinmyung Jung; Mijin Kwon; Sunghwa Bae; Soorin Yim; Doheon Lee
Journal:  BMC Syst Biol       Date:  2018-03-05

10.  Identification of the Acetylation and Ubiquitin-Modified Proteome during the Progression of Skeletal Muscle Atrophy.

Authors:  Daniel J Ryder; Sarah M Judge; Adam W Beharry; Charles L Farnsworth; Jeffrey C Silva; Andrew R Judge
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.